The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modality (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging and multicenter study, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF in multicenter population.
left ventricular ejection fraction (LVEF)≥50%；
N-terminal pro-b type natriuretic peptide (NT-proBNP)>220pg/ml or b type natriuretic peptide (BNP) >80 pg/ml;
symptoms and syndromes of heart failure;
At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
Severe arrhythmia;
Severe primary cardiac valvular disease;
This study is a prospective, multicenter study with HFpEF patients, diagnosed based on 2016 and 2019 European Society of Cardiology (ESC) concensus. The inclusion criteria include left ventricular ejection fraction (LVEF)≥50%；N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml; symptoms and syndromes of heart failure; and at least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities. We exclude patients with special cardiomyopathy, ; Infarction, myocardial fibrosis caused by ischemic cardiomyopathyand acute coronary syndrome; Severe arrhythmia; Severe primary cardiac valvular disease; Restrictive pericardial disease; Refuse to participate in the study.
Case-control
Prospective
Not listed
All-cause Death
the incidence of all-cause death
Cardiovascular Death
the incidence of cadridovascular death
Hospitalization Due to Heart Failure
the incidence of Hospitalization Due to Heart Failure
Implantable cardioverter-defibrillator Implantation
the incidence of Implantable cardioverter-defibrillator Implantation
Heart Transplantation
the incidence of Heart Transplantation
Pacemaker Implantation
the incidence of Pacemaker Implantation
Atrial fibrillation
the incidence of Atrial fibrillation
Click on the lead sponsor to view all of their trials.
Chinese Academy of Medical Sciences, Fuwai Hospital
Lead sponsor
Peking Union Medical College Hospital
Collaborator
Beijing Anzhen Hospital
Collaborator
China-Japan Friendship Hospital
Collaborator
Guangdong Provincial People's Hospital
Collaborator
